Details

---

Manufacturer
Reliance Life Sciences Pvt. Ltd (Plant 6)(INDIA)

Registraction Number
MAL24086017AZ

Content:

• Active Ingredient: Bortezomib 1 mg (lyophilized)
• Excipients: Mannitol (Pyrogen free), Tertiary Butanol, Water for Injection, Nitrogen NF (Process Aid)

Indication:
BortiRel is indicated for the treatment of:

• Multiple Myeloma: For patients who have received at least one prior therapy.
• Mantle Cell Lymphoma: For previously untreated patients who are unsuitable for haematopoietic stem cell transplantation.

Instructions:

1. Reconstitution: BortiRel should be reconstituted with 0.9% Sodium Chloride Injection before administration.
2. Administration: It is administered intravenously as a 3 to 5 second bolus injection.
3. Dosage: The recommended starting dose is 1.3 mg/m² body surface area. For multiple myeloma, it is typically given in combination with oral melphalan and prednisone1.
4. Cycle: Treatment cycles usually consist of twice-weekly administration for the first four cycles, followed by once-weekly administration for the next five cycles.
5. Precautions: Ensure platelet count is at least 70 x 10^9/L and absolute neutrophil count (ANC) is at least 1.0 x 10^9/L before initiating therapy.